TPO-RAs offer a safer and more effective way to manage this condition.[45] In a study conducted in 2020, a thrombopoietin receptor agonist (TPO-RA) was approved for the treatment of immune thrombocytopenia. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.